Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (362)	1/5/1999 10:53:00 PM
From: JOEBT1	Read Replies (1) \| Respond to of 1073

Richard--The PRs from CEGE and AVGN both cite the work of Mark Kay of Stanford who is collaborating with AVGN according to AVGN's PR. However CEGE states the following on their patent position. " Cell Genesys holds a broad U.S. patent covering all gene therapy products that utilize AAV vectors to deliver genes as therapeutic agents. The patent includes composition of matter claims which cover the essential component of any AAV gene delivery system, specifically any recombinant AAV vector products, free of contaminating wild-type AAV, regardless of method of production. Cell Genesys has one of the largest patent estates in gene therapy with over 150 issued or granted patents and over 300 pending patent applications. " CEGE's patent and financial position seem to be much stronger than AVGN.